Episode 2: Why Great Science Doesn’t Sell Itself | Biotech Marketing, AI & Scientific Communication

Why doesn’t great science always sell itself?

In Episode 2 of Inside the Industry, Kim Laipple sits down with Jason, Founder & CEO of Sumba Scientific, to explore the intersection of science, business, marketing, commercialization, and AI in the life sciences industry.

Jason shares his journey from working as a biochemist and cancer drug discovery researcher to building a marketing agency focused specifically on biotech and life science companies.

Together, Kim and Jason examine why having strong scientific technology isn't enough to guarantee commercial success—and why understanding your customers, their problems, and the value of your solution is essential.

📙 In This Episode:
✔ Why great science doesn't automatically sell itself
✔ Jason's journey from bench science to biotech marketing
✔ Transitioning from scientific research to sales and strategy
✔ How biotech companies can identify ideal customers
✔ Customer discovery and product-market fit
✔ Marketing problems vs. product and sales problems
✔ How scientific data builds credibility and trust
✔ Why brand awareness alone doesn't generate revenue
✔ Sales vs. marketing in early-stage biotech companies
✔ How customer applications shape marketing messaging
✔ The impact of AI on biotech and life science marketing
✔ AI-generated content vs. human creativity
✔ Why AI answers should be "trust but verify"
✔ Transparency and scientific data validation
✔ Misinformation and trust in science
✔ The future of life science marketing and commercialization

Whether you're a scientist, biotech founder, life science entrepreneur, marketer, sales professional, or innovation leader, this conversation offers practical insights into turning complex scientific innovation into clear value, stronger customer relationships, and commercial success.

What does it really take to bring breakthrough therapies from the lab to patients?

In the premiere episode of Inside the Industry, Kim Laipple sits down with Patrick Doyle, CEO of Trio Pharmaceuticals, to discuss the realities of biotech leadership, drug development, fundraising, and innovation.

With more than 25 years of experience spanning startups and global pharmaceutical leaders including Novo Nordisk and Roche, Patrick shares the pivotal moments that shaped his career, lessons learned through both success and failure, and why the best biotech leaders let data—not emotion—guide critical decisions.

The conversation explores the challenges of raising capital in today's market, the importance of experienced leadership teams, Trio's innovative Trailbody™ platform for targeted cancer therapies, and emerging technologies such as artificial intelligence and synthetic organ development that could reshape the future of medicine.

Whether you're a biotech executive, scientist, investor, entrepreneur, or simply passionate about healthcare innovation, this episode offers valuable insights into the people and decisions driving the life sciences industry forward.

• Patrick's journey from scientist to biotech CEO
• Leadership lessons from Novo Nordisk and Roche
• Navigating setbacks in drug development
• What investors look for in biotech companies
• How Trio's Trailbody™ platform targets cancer cells
• Why "kill early" is a critical biotech philosophy
• AI's role in drug discovery and development
• The future of regenerative medicine and synthetic organs
• Building resilient teams and making data-driven decisions

Patrick Doyle is the CEO of Trio Pharmaceuticals. Throughout his career, he has helped build and lead multiple biotechnology companies, raised more than $300 million across seven ventures, and contributed to four successful acquisitions. Prior to Trio, he served in executive leadership roles at K Bio, Stellexis Bioscience, Novo Nordisk, and Roche.

Trio Pharmaceuticals: https://www.triopharmaceuticals.com

Patrick Doyle: https://www.linkedin.com/in/pj-doyle/

Scientific Search: https://www.scientificsearch.com

If you enjoyed this episode, be sure to subscribe, leave a review, and share it with colleagues in biotech, pharmaceuticals, and healthcare innovation.

#InsideTheIndustry #Biotech #LifeSciences #Pharmaceuticals #DrugDevelopment #Biotechnology #Leadership #CancerResearch #HealthcareInnovation #ScientificSearch